Maat Pharma (XPAR:MAAT) LT-Debt-to-Total-Asset: 0.29 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:MAAT Maat Pharma SA XPAR:MAAT
27 GF Score
Price €2.73
GF Value €10.63
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Maat Pharma LT-Debt-to-Total-Asset?

Maat Pharma XPAR:MAAT +1.30% 27 LT-Debt-to-Total-Asset is 0.29 as of Dec. 2025. GuruFocus rates XPAR:MAAT with a GF Score™ of 27/100 and a GF Value™ of €10.63 (Possible Value Trap). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Maat Pharma's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.29.

Maat Pharma's long-term debt to total assets ratio declined from Dec. 2024 (0.33) to Dec. 2025 (0.29). It may suggest that Maat Pharma is progressively becoming less dependent on debt to grow their business.

Maat Pharma  (XPAR:MAAT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Maat Pharma LT-Debt-to-Total-Asset Related Terms

Maat Pharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Maat Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maat Pharma LT-Debt-to-Total-Asset Chart

Maat Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.09 0.19 0.25 0.33 0.29

Maat Pharma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.20 0.33 0.24 0.29
XPAR:MAAT
27GF Score
Maat Pharma SA XPAR:MAAT
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maat Pharma LT-Debt-to-Total-Asset Calculation

Maat Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=12.911/44.551
=0.29

Maat Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=12.911/44.551
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.29 mean?
Maat Pharma (XPAR:MAAT) has a LT-Debt-to-Total-Asset of 0.29 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Maat Pharma and its competitors.
Is Maat Pharma's LT-Debt-to-Total-Asset too high?
Maat Pharma's current LT-Debt-to-Total-Asset is 0.29. Overall, Maat Pharma has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Maat Pharma's LT-Debt-to-Total-Asset compare to VRTX and REGN?
Maat Pharma's LT-Debt-to-Total-Asset of 0.29 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Maat Pharma and its competitors. Maat Pharma's current LT-Debt-to-Total-Asset is 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Maat Pharma (XPAR:MAAT) is currently considered Possible Value Trap. The stock's GF Value™ is €10.63, compared to a current price of €2.73 — trading 74.4% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.29. Maat Pharma's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Maat Pharma (XPAR:MAAT), the current LT-Debt-to-Total-Asset is 0.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Maat Pharma (XPAR:MAAT) Overvalued in 2026?

Based on GuruFocus' analysis, Maat Pharma stock appears to be undervalued. The current stock price of €2.73 is trading 74.4% below its estimated GF Value™ of €10.63. GuruFocus considers Maat Pharma to be Possible Value Trap.

Key valuation signals for XPAR:MAAT:

  • LT-Debt-to-Total-Asset: 0.29
  • GF Value™: €10.63 vs. price of €2.73 (74.4% below fair value)
  • GF Score™: 27/100 with 3 warning signs

No single metric tells the full story. See the XPAR:MAAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Maat Pharma Business Description

Other Exchanges 4RD:Germany
Address 70 Avenue Tony Garnier, Lyon, FRA, 69007
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.
27GF Score

Get the complete analysis for XPAR:MAAT

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.73
Price
€10.63
GF Value